Results 11 to 20 of about 16,906 (241)

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. [PDF]

Neurol Ther, 2022
Introduction Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa are needed. We have evaluated
Hauser RA, Favit A, Hewitt LA, Lindsten A, Gorny S, Kymes S, Isaacson SH.   +6 more
europepmc   +4 more sources

Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies [PDF]

Clinical Medicine Insights: Cardiology, 2020
Neurogenic orthostatic hypotension (nOH) is a subtype of orthostatic hypotension in which patients have impaired regulation of standing blood pressure due to autonomic dysfunction. Several primary and secondary causes of this disease exist.
Dinesh K Kalra, Anvi Raina, Sumit Sohal
doaj   +4 more sources

Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. [PDF]

Clin Auton Res
We previously reported that single doses of the norepinephrine transporter inhibitor, atomoxetine, increased standing blood pressure (BP) and ameliorated symptoms in patients with neurogenic orthostatic hypotension (nOH).
Mwesigwa N, Millar Vernetti P, Kirabo A, Black B, Ding T, Martinez J, Palma JA, Biaggioni I, Kaufmann H, Shibao CA.   +9 more
europepmc   +4 more sources

Diagnosis and management of neurogenic orthostatic hypotension [PDF]

Annals of Clinical Neurophysiology, 2023
Orthostatic hypotension is a sustained and pathological drop in blood pressure upon standing. Orthostatic hypotension can be due to non-neurogenic conditions or autonomic disorders. Impaired baroreflex-mediated vasoconstriction and insufficient release of norepinephrine play key roles in the pathophysiology of neurogenic orthostatic hypotension.
Woohee Ju, Dong-In Sinn
semanticscholar   +3 more sources

Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer [PDF]

Neurology and Therapy, 2019
Abstract Parkinson disease (PD) is associated with a variety of motor and non-motor clinical manifestations, including cardiovascular autonomic dysfunction. Neurogenic orthostatic hypotension (nOH) is a potentially serious manifestation of cardiovascular
Jeremy K. Cutsforth-Gregory, Phillip A. Low   +1 more
doaj   +5 more sources

Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopa [PDF]

Journal of Market Access & Health Policy, 2022
Background Symptoms of neurogenic orthostatic hypotension (nOH), including lightheadedness/dizziness, presyncope, syncope, and falls, can lead to impaired functional ability and reduced quality of life.
Clément François, Nicola Germain, Renata Majewska, Vanessa Taieb, L. Arthur Hewitt, Steven Kymes   +5 more
doaj   +3 more sources

Carbon dioxide for neurogenic orthostatic hypotension in adults: a novel therapy. [PDF]

Eur Heart J
Baker JR, Ranada SI, Incognito AV, Sheldon RS, Morillo CA, Wilson RJA, Phillips AA, Raj SR.   +7 more
europepmc   +3 more sources

Primary neurogenic orthostatic hypotension [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1970
Eight further cases of neurogenic orthostatic hypotension are described together with a necropsy study on one case. Three cases showed evidence of autonomic dysfunction in isolation, while in five cases this was accompanied by evidence of more diffuse central nervous system degeneration.
R.C. Hughes, N.E.F. Cartlidge, P Millac
openalex   +4 more sources

Neurogenic Orthostatic Hypotension in Parkinson Disease-A Narrative Review of Diagnosis and Management. [PDF]

J Clin Med
Background: Neurogenic orthostatic hypotension (NOH) is a significant non-motor manifestation of Parkinson’s disease (PD), that substantially affects patient disability and has a powerful impact on the quality of life of PD patients, while also ...
Grosu C, Noea O, Maștaleru A, Ignat EB, Leon MM.   +4 more
europepmc   +2 more sources

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension [PDF]

BMC Neurology, 2017
Background Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies.
Italo Biaggioni, L. Arthur Hewitt, Gerald J. Rowse, Horacio Kaufmann   +3 more
doaj   +2 more sources